{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:03:51Z","timestamp":1792796631724,"version":"4.5.0"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Multiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system (CNS). There is a significant delay in diagnosing MS as the symptoms and tests overlap with other diseases. Blood-based biomarkers, which quantify fragments of proteins involved in MS pathophysiology, have the potential as diagnostic biomarkers. In this study, we evaluated biomarkers by immunoassays, of tissue destruction, reflected by biglycan degraded by matrix metalloproteinases (MMPs) (BGM), cathepsin S-degraded nidogen (NIC), and MMP-degraded secreted protein acidic and rich in cysteine (SPARC-M) in healthy donors and patients diagnosed with MS. The biomarkers were able to separate the two groups with an AUC\u202f=\u202f0.710, AUC\u202f=\u202f0.765, and AUC\u202f=\u202f0.875, respectively. These pathologically released protein fragments could potentially be used as biomarkers in clinical management providing a specific protein fingerprint.<\/jats:p>","DOI":"10.3389\/fneur.2024.1425046","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T15:13:25Z","timestamp":1735658005000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Diagnostic potential of blood-based biomarkers in multiple sclerosis"],"prefix":"10.3389","volume":"15","author":[{"given":"Signe","family":"Holm Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Manoel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Christine","family":"Bay-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of Multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"J Am Med Assoc"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"103361","DOI":"10.1016\/j.msard.2021.103361","article-title":"Factors driving delayed time to multiple sclerosis diagnosis: results from a population-based study","volume":"57","author":"Patti","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1212\/NXI.0000000000000520","article-title":"Clinical utility of a molecular signature in inflammatory demyelinating disease","volume":"6","author":"Pachner","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflam"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s11910-022-01227-1","article-title":"An update on diagnostic laboratory biomarkers for Multiple sclerosis","volume":"22","author":"Kaisey","year":"2022","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple sclerosis Pathology","volume":"8","author":"Lassmann","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/j.1750-3639.2010.00399.x","article-title":"Extracellular matrix in Multiple sclerosis lesions: Fibrillar collagens, Biglycan and Decorin are upregulated and associated with infiltrating immune cells","volume":"20","author":"Mohan","year":"2010","journal-title":"Brain Pathol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1097\/01.jnen.0000173894.09553.13","article-title":"Basement membrane proteins in Multiple sclerosis-associated inflammatory cuffs: Potential role in influx and transport of leukocytes","volume":"64","author":"Van Horssen","year":"2005","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1191\/1352458504ms1023oa","article-title":"Proteomic analysis of multiple sclerosis cerebrospinal fluid","volume":"10","author":"Hammack","year":"2004","journal-title":"Multip Sclerosis J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1755-1536-6-9","article-title":"Biglycan fragmentation in pathologies associated with extracellular matrix remodeling by matrix metalloproteinases","volume":"6","author":"Genovese","year":"2013","journal-title":"Fibrogenesis Tissue Repair"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.neo.2017.01.008","article-title":"Nidogen-1 degraded by Cathepsin S can be quantified in serum and is associated with non-small cell lung Cancer","volume":"19","author":"Willumsen","year":"2017","journal-title":"Neoplasia (United States)"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1080\/15384047.2018.1480887","article-title":"A fragment of SPARC reflecting increased collagen affinity shows pathological relevance in lung cancer \u2013 implications of a new collagen chaperone function of SPARC","volume":"19","author":"Kehlet","year":"2018","journal-title":"Cancer Biol Ther"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1425046\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T15:13:27Z","timestamp":1735658007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1425046\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":12,"alternative-id":["10.3389\/fneur.2024.1425046"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1425046","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]},"article-number":"1425046"}}